VesugenВезуген
What the studies found
Observational study · 2013
Vezugen in postoperative chronic lower-limb arterial insufficiency
- Clinical and blood-flow findings
- Qualitative improvement reported; numerical effects and a comparator arm not established.
Clinical and ultrasound blood-flow improvement was reported after Vezugen treatment; the abstract supplies no numerical effect estimate.
Study notes · methods, sources and limitations
Participants or model 41 postoperative patients with chronic lower-limb ischemia
Design 41 postoperative patients; before/after clinical and ultrasound assessment of Vezugen treatment.
Important limitations
- No control arm, masking or numerical treatment effect established from the abstract. Distinct from PMID 25051774 (2014); participant overlap remains unresolved. The findings apply to the preparation tested. Efficacy of purified KED remains uncertain.
- Separate 2013 publication; overlap with the 2014 erectile-dysfunction report is unresolved.
Advances in Gerontology / Uspekhi Gerontologii. 2013;26(2):292–296. PMID 28976154 · Original clinical journal publication
Animal research · 2008
Vesugen in the separate adult-hypoxia arm
Study of multiple preparations
- Respiration arrest
- 88 ± 9 secondsSaline 72 ± 10 seconds; n=10/groupNo numerical p-value supplied
- Adult mortality
- 10%Saline 10%; very small groups, no verified mortality difference test
In adult male rats, Vesugen was associated with 88 ± 9 seconds to respiration arrest versus 72±10 with saline. This arm did not expose pregnant animals to Vesugen.
Study notes · methods, sources and limitations
Participants or model Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Design Two distinct experiments: five-day pretreatment in adult males, and maternal Pinealon after gestation-day-10 hypoxia. Offspring cerebellar cells tested at day 12; open-field behavior at four weeks, stratified by maternal hypoxia sensitivity.
Important limitations
- Only Pinealon was studied in the maternal arm of this publication. Adult hypoxia findings are adjacent context, not pregnancy-safety evidence.
- Animal injury experiments do not establish human pregnancy safety. Epitalon, Vilon and Vesugen were tested only in the adult-male arm of this paper. Number of pregnant dams, randomization, masking and litter-adjusted statistics are not established. Offspring are not independent maternal exposures. Table 1 mortality conflicts with the prose; do not convert the latter into a verified excess risk. Vilon and Epitalon respiration findings marked p<0.08 are not demonstrated p<0.05 results. The paper prints an Epitalon sequence ending in Arg; established Epitalon identity is Ala-Glu-Asp-Gly. That apparent source error is retained as an identity warning.
Doklady Biological Sciences. 2008;418:7–10; Russian original Doklady Akademii Nauk 418(3):419–422. PMID 21249538 · Original journal publication
Comparison in people · 2012
Peptide combinations investigated in professional drivers
Study of multiple preparations
- Sociodemographic associations
- Not statistically significantp>0.1
- Peptide-associated psychoemotional/adaptation changes
- Statistically significant range reportedp<0.001–0.05
- Preferred combination in the authors’ report
- Pinealon + VesugenSeparate treatment-arm sizes and absolute outcome changes not stated
The abstract describes occupational psychoemotional differences and reports changes with peptide bioregulators, including combined Pinealon and Vezugen.
Study notes · methods, sources and limitations
Participants or model 150 male lorry drivers and 150 male metal craftsmen in the occupational comparison
Design 150 male lorry drivers (43.3 ± 0.9 years) and 150 male metal craftsmen (42.8 ± 0.9 years); three psychological-adaptation categories.
Important limitations
- The 300-person occupational comparison is not a verified treatment-group size; Pinealon and Vesugen were combined.
- The occupational cohort size is not a verified randomized-treatment sample size. Randomization, blinding, and intervention-group sizes are not established from the abstract. Combination findings do not identify either peptide’s independent contribution or demonstrate fewer driving accidents.
- The 300-person occupational comparison is not a verified randomized-treatment denominator.
Adv Gerontol. 25(4):718–728 · Indexed abstract
About Vesugen
Names in this research collection
KED · Vezugen
Vesugen is the KED tripeptide (Lys–Glu–Asp) in the short-peptide catalogue, studied in vascular and cell-aging research. It is not the whole vessel extract Vasolin/Slavinorm.
Identity / background source ↗
Research background
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Autoimmune research: disease-specific findings, immune effects and open questions ↗
Pregnancy and offspring research
In adult male rats, Vesugen was associated with 88 ± 9 seconds to respiration arrest versus 72±10 with saline. This arm did not expose pregnant animals to Vesugen.
Only Pinealon was studied in the maternal arm of this publication. Adult hypoxia findings are adjacent context, not pregnancy-safety evidence.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
More study findings
Observational study · 2015
Aging-marker changes included mixed signals
Study of multiple preparations
- Biological-age indicators
- Authors reported favorable changes after Pinealon or Vesugen; comparative effect size unavailable
- Oxidation and blood-cell markers
- Prooxidant activity and lower circulating CD34-positive markers also reported
The authors reported changes in biological-age indicators after Pinealon and Vesugen. They also reported prooxidant activity and lower circulating CD34-positive cell markers.
Study notes · methods, sources and limitations
Participants or model Adults aged 41–83 with multiple conditions and organic brain syndrome in remission
Design Adults aged 41–83 with multiple conditions and organic brain syndrome in remission; Pinealon and Vesugen studied.
- Printed total enrollment
- 32
- Printed sex breakdown
- 18 men + 12 women = 30; does not reconcile with printed total
Important limitations
- The reported total does not match the sex breakdown. Pinealon-specific effects cannot be separated from the available report.
- The abstract states 32 participants but lists 18 men and 12 women; the reported participant totals differ. Allocation, comparator details and preparation-specific effects require the full paper. The biomarker findings do not establish clinical harm, longevity benefit or genetic safety; favorable author conclusions should not erase the adverse-direction signals.
- The abstract says 32 participants while listing 18 men and 12 women. It does not isolate preparation-specific effects or establish longevity, genetic safety or clinical harm.
Advances in gerontology = Uspekhi gerontologii; 2015 · Indexed abstract
Observational study · 2016
Personified prevention of diseases under the conditions of the Far North
Study of multiple preparations
- Sick-leave certificates
- 18 → 102014 → 2015; whole program
- Days unfit for work
- 119 → 602014 → 2015; whole program
- Seasonal morbidity
- No statistically reliable improvement reported
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
More reported outcomes
- Narrative/table discrepancy
- Narrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Study notes · methods, sources and limitations
Participants or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Design 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Important limitations
- One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Vrach. 2016;(6):64–66 · Journal publication
Lab research · 2012
Peptides tissue-specifically stimulate cell differentiation during their aging
Study of multiple preparations
- Differentiation markers
- CXCL12/Hoxa3 or CXCL12/WEGC1 expression increased in the corresponding cultures
Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.
Study notes · methods, sources and limitations
Participants or model Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
Design Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
- Preparation assignments
- Pancragen KEDW → pancreas; Bronchogen AEDL → bronchial cells; Vesugen KED → prostatic fibroblasts
Important limitations
- Different peptides were tested in different cell types; this is not a combination trial or evidence of organ recovery in patients. No numerical effect sizes are supplied.
Bulletin of experimental biology and medicine 2012 · Journal publication
Review of earlier studies · 2026
Review connects vascular extracts, KED and AEDR experimental research
Study of multiple preparations
- Preparations reviewed
- Vascular polypeptide preparation, KED and AEDR
- Endothelial findings
- KED restored elevated ET-1 expression toward normal in reported culturesCultures derived from patients are not a clinical treatment trial
- Cardiac findings
- AEDR experimental cardioprotection summarizedAnimal experiments; no new human trial
The review brings together vascular polypeptide, KED and AEDR research. It describes changes in endothelial endothelin-1 expression, vascular hemodynamics and experimental myocardial injury. These preparation-specific observations are preclinical; the review supplies no new human cardiovascular efficacy trial.
Study notes · methods, sources and limitations
Participants or model Review of vascular-polypeptide, KED and AEDR experiments in endothelial cultures and animal cardiovascular models.
Important limitations
- Review of earlier experiments, not independent replication. Vascular extracts, KED and AEDR are different preparations; effects cannot be transferred between them. Exact publication day is not supplied by the index; newly indexed 28 October 2026.
Advances in gerontology = Uspekhi gerontologii 39(4) · Journal publication
Performance research in context
- Compound class
- Bioregulator
- Research collection
- Peptide bioregulation · editorial grouping
- Research institutions
- No institutional affiliation recorded
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Original human reports linked; methods and cohort overlap need appraisal
Study methods
Abstract-level review
Independent replication
Independent replication not established by this collection
Source access
See source-specific abstracts, institute reports and explicit review scopes
Safety evidence
Incomplete assessment; findings do not establish safety for personal use
Open a topic for the evidence assessment.
Patents and claimed inventions
These 3 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Linked sources
Explore the research map and unresolved leads ↗
Explore related historical combinations ↗
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗